Compare Stocks: NUVB, CRNX, PTGX, and TGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$83.52	$54.15	$25.83 ▼ $84.00	$8.81B	0.23	8.82 million shs	1.86 million shs
NUVB Nuvation Bio	$6.33 -0.1%	$5.60	$2.18 ▼ $9.75	$2.20B	1.52	6.41 million shs	4.89 million shs
PTGX Protagonist Therapeutics	$136.64	$120.38	$50.49 ▼ $143.29	$8.79B	1.79	700,312 shs	548,760 shs
TGTX TG Therapeutics	$52.03	$50.48	$25.28 ▼ $59.30	$7.96B	1.62	2.06 million shs	2.49 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	0.00%	-0.25%	+97.77%	+114.04%	+200.00%
NUVB Nuvation Bio	0.00%	-1.85%	+11.28%	+41.36%	+184.95%
PTGX Protagonist Therapeutics	0.00%	+0.39%	+3.81%	+38.90%	+153.84%
TGTX TG Therapeutics	0.00%	-7.16%	-2.40%	+53.78%	+48.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$83.52	$54.15	$25.83 ▼ $84.00	$8.81B	0.23	8.82 million shs	1.86 million shs
NUVB Nuvation Bio	$6.33 -0.1%	$5.60	$2.18 ▼ $9.75	$2.20B	1.52	6.41 million shs	4.89 million shs
PTGX Protagonist Therapeutics	$136.64	$120.38	$50.49 ▼ $143.29	$8.79B	1.79	700,312 shs	548,760 shs
TGTX TG Therapeutics	$52.03	$50.48	$25.28 ▼ $59.30	$7.96B	1.62	2.06 million shs	2.49 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	0.00%	-0.25%	+97.77%	+114.04%	+200.00%
NUVB Nuvation Bio	0.00%	-1.85%	+11.28%	+41.36%	+184.95%
PTGX Protagonist Therapeutics	0.00%	+0.39%	+3.81%	+38.90%	+153.84%
TGTX TG Therapeutics	0.00%	-7.16%	-2.40%	+53.78%	+48.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-3.02% Downside
NUVB Nuvation Bio	2.64	Moderate Buy	$12.88	103.53% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$123.00	-9.98% Downside
TGTX TG Therapeutics	2.44	Hold	$58.50	12.44% Upside

Current Analyst Ratings Breakdown

Latest NUVB, CRNX, PTGX, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
7/28/2026	CRNX Crinetics Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$55.00 ➝ $85.00
7/27/2026	TGTX TG Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $86.00
7/27/2026	CRNX Crinetics Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	NUVB Nuvation Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $21.00
7/23/2026	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
7/22/2026	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/17/2026	CRNX Crinetics Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NUVB Nuvation Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	PTGX Protagonist Therapeutics	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$165.00
7/17/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$18.07M	487.37	N/A	N/A	$9.71 per share	8.60
NUVB Nuvation Bio	$62.90M	35.02	N/A	N/A	$0.88 per share	7.19
PTGX Protagonist Therapeutics	$74.06M	118.65	N/A	N/A	$9.83 per share	13.90
TGTX TG Therapeutics	$616.29M	12.92	$2.80 per share	18.57	$4.08 per share	12.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.13	N/A	N/A	N/A	-2,747.18%	-43.96%	-39.61%	8/4/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.43	N/A	N/A	N/A	-102.06%	-44.10%	-23.80%	8/6/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	-$1.81	N/A	N/A	N/A	-154.88%	-17.76%	-16.47%	8/5/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.86	18.19	17.70	1.30	65.95%	88.73%	43.44%	8/3/2026 (Estimated)

Latest NUVB, CRNX, PTGX, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	N/A	N/A	N/A	$27.03 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.23	N/A	N/A	N/A	$199.81 million	N/A
8/4/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	N/A	N/A	N/A	$14.84 million	N/A
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	N/A	N/A	N/A	$229.77 million	N/A
5/7/2026	Q1 2026	CRNX Crinetics Pharmaceuticals	-$1.22	-$1.23	-$0.01	-$1.23	$8.51 million	$10.73 million
5/6/2026	Q1 2026	TGTX TG Therapeutics	$0.23	$0.12	-$0.11	$0.12	$200.33 million	$204.92 million
5/5/2026	Q1 2026	PTGX Protagonist Therapeutics	-$0.5004	$0.05	+$0.5504	$0.05	$11.70 million	$56.37 million
5/4/2026	Q1 2026	NUVB Nuvation Bio	-$0.0280	$0.01	+$0.0380	$0.01	$66.22 million	$83.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	18.60	18.56
NUVB Nuvation Bio	0.15	7.44	7.24
PTGX Protagonist Therapeutics	N/A	17.76	17.76
TGTX TG Therapeutics	1.28	5.81	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
NUVB Nuvation Bio	61.67%
PTGX Protagonist Therapeutics	98.63%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	3.80%
NUVB Nuvation Bio	30.11%
PTGX Protagonist Therapeutics	5.19%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	105.44 million	101.43 million	Optionable
NUVB Nuvation Bio	60	348.20 million	243.36 million	Optionable
PTGX Protagonist Therapeutics	120	64.31 million	60.97 million	Optionable
TGTX TG Therapeutics	290	153.08 million	139.51 million	Optionable

NUVB, CRNX, PTGX, and TGTX Headlines

Recent News About These Companies

Renaissance Technologies LLC Buys Shares of 340,900 TG Therapeutics, Inc. $TGTX

August 2 at 5:03 AM | marketbeat.com

TG Therapeutics (TGTX) to Post Quarterly Earnings on Monday

August 2 at 1:40 AM | americanbankingnews.com

SummitTX Capital L.P. Sells 32,875 Shares of TG Therapeutics, Inc. $TGTX

August 1 at 5:51 AM | marketbeat.com

Edgestream Partners L.P. Buys Shares of 168,351 TG Therapeutics, Inc. $TGTX

July 31 at 4:16 AM | marketbeat.com

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

July 29, 2026 | globenewswire.com

TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth

July 27, 2026 | zacks.com

TG Therapeutics (TGTX) to Post Earnings on Monday

July 27, 2026 | marketbeat.com

Fifth Third Bancorp Grows Stock Position in TG Therapeutics, Inc. $TGTX

July 26, 2026 | marketbeat.com

Hsbc Holdings PLC Has $3.56 Million Stock Holdings in TG Therapeutics, Inc. $TGTX

July 25, 2026 | marketbeat.com

Knott David M Jr Has $2.99 Million Position in TG Therapeutics, Inc. $TGTX

July 24, 2026 | marketbeat.com

Principal Financial Group Inc. Sells 182,261 Shares of TG Therapeutics, Inc. $TGTX

July 22, 2026 | marketbeat.com

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

July 21, 2026 | prnewswire.com

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

July 16, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

July 16, 2026 | theglobeandmail.com

Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)

July 15, 2026 | theglobeandmail.com

HC Wainwright Forecasts Reduced Earnings for TG Therapeutics

July 15, 2026 | marketbeat.com

TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright

July 15, 2026 | theglobeandmail.com

HC Wainwright Cuts Earnings Estimates for TG Therapeutics

July 14, 2026 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 14, 2026 | marketbeat.com

TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations

July 13, 2026 | insidermonkey.com

HC Wainwright Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) Stock

July 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NUVB, CRNX, PTGX, and TGTX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$83.52 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$84.00 +0.48 (+0.57%)

As of 07/31/2026 07:54 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Nuvation Bio NYSE:NUVB

$6.33 0.00 (-0.06%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$6.33 +0.00 (+0.06%)

As of 07/31/2026 07:40 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Protagonist Therapeutics NASDAQ:PTGX

$136.64 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$136.73 +0.09 (+0.07%)

As of 07/31/2026 07:34 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

TG Therapeutics NASDAQ:TGTX

$52.03 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$52.13 +0.10 (+0.18%)

As of 07/31/2026 07:59 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NUVB, CRNX, PTGX, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NUVB, CRNX, PTGX, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NUVB, CRNX, PTGX, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NUVB, CRNX, PTGX, and TGTX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

Nuvation Bio NYSE:NUVB

Protagonist Therapeutics NASDAQ:PTGX

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NUVB, CRNX, PTGX, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NUVB, CRNX, PTGX, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NUVB, CRNX, PTGX, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NUVB, CRNX, PTGX, and TGTX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

Nuvation Bio NYSE:NUVB

Protagonist Therapeutics NASDAQ:PTGX

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools